CONNEQT Health (CQT.AX) Stock Price

CONNEQT Health Price

ASX·CLOSED
0.00
​
Market closed

Revenue at CONNEQT Health has contracted by 1.0% per year over the past 19 years to 3.55 M AUD. For CONNEQT Health, the net margin of -511.9% is down versus -105.5% a few years ago.

CONNEQT Health stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CONNEQT Health business model & stock analysis

CardieX Ltd. generates revenue through its medical device business focused on cardiovascular management, targeting healthcare providers and pharmaceutical companies. The company offers clinical trial services across three geographic segments: Americas, Europe (including Middle East and Africa), and Asia Pacific (covering Asia and Australia/New Zealand). These services include study protocol assistance, operator training, data management, and technical support for global pharmaceutical trials. SphygmoCor technology is a key product used in clinical trials for therapeutic areas such as hypertension, renal disease, and heart failure. The firm's revenue streams are derived from its clinical trial services and SphygmoCor technology, which are sold to pharmaceutical companies conducting global trials. The Americas segment handles the global pharmaceutical trials business, while Europe and Asia Pacific segments support regional trial operations. SphygmoCor technology is specifically utilized in trials for cardiovascular and metabolic conditions, including COPD and diabetes. CardieX Ltd. serves pharmaceutical companies and healthcare institutions requiring cardiovascular management solutions and clinical trial support. Its products and services are tailored to therapeutic areas like hypertension, renal disease, heart failure, and inflammatory processes, with a focus on automated data transfer and expert over-read services for trial accuracy.

Frequently asked questions about CONNEQT Health

Converted at the current exchange rate, the CONNEQT Health share trades at 0.00 EUR (0.00 AUD).

The CONNEQT Health share (CQT.AX) is listed on 1 stock exchanges, including: ASX (CDX.AX).

The expected revenue of CONNEQT Health is 51.18 M AUD. This figure is based on current financial data and reflects the company's business performance.

The profit cannot currently be calculated for CONNEQT Health.

The P/E ratio cannot be calculated for CONNEQT Health at the moment.

The price-to-sales ratio (P/S) of CONNEQT Health is currently 0.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CONNEQT Health stock.

The Eulerpool Quality Score for CONNEQT Health is 3/10.

The ISIN of CONNEQT Health is AU0000420739. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CONNEQT Health is A2JN9Z. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CONNEQT Health is CQT.AX. The ticker symbol is used to trade CONNEQT Health shares on the stock exchange.

Fair ValueTerminal
0.00 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
136,704.62 AUD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cardiex.com
Country
Australia
Currency
AUD
Initial public offering
Nov 9, 2005
ISIN
AU0000420739
Cusip
Q2096E102
Sedol
BFXFSL3
Market capitalization
1.84 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
—
P/Ee 2027
0.04
P/S
P/Se
0.04
EV/EBIT
—
P/B Ratio
2.90
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-764.26 %
Last updated Nov 19, 2026, 3:50 AM

CONNEQT Health Peer Group

CONNEQT Health Ticker

ASX · CDX.AX